Putnam Announces Distribution Rates for Open End Funds
BOSTON--(BUSINESS WIRE)--
The Trustees of The Putnam Funds declared the following distributions.
|
|
|
|
RECORD/ |
PAYMENT |
FUND NAME AND DISTRIBUTIONS |
EX DATE |
DATE |
|
|
|
|
|
|
Putnam High Yield Fund - Class B Shares (PHYBX) |
|
|
$0.0200 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam High Yield Fund - Class C Shares (PHYLX) |
|
|
$0.0200 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam High Yield Fund - Class M Shares (PHYMX) |
|
|
$0.0230 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam High Yield Fund – Class R Shares (PFJAX) |
|
|
$0.0230 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam High Yield Fund - Class Y Shares (PHAYX) |
|
|
$0.0250 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam High Yield Fund – Class R6 Shares (PHYUX) |
|
|
$0.0260 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam Income Fund - Class B Shares (PNCBX) |
|
|
$0.0130 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam Income Fund - Class C Shares (PUICX) |
|
|
$0.0130 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam Income Fund - Class M Shares (PNCMX) |
|
|
$0.0160 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam Income Fund - Class R Shares (PIFRX) |
|
|
$0.0160 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam Income Fund - Class Y Shares (PNCYX) |
|
|
$0.0200 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam Income Fund - Class R5 Shares (PINFX) |
|
|
$0.0200 per share investment income |
1/23/20 |
1/27/20 |
|
|
|
Putnam Income Fund - Class R6 Shares (PINHX) |
|
|
$0.0200 per share investment income |
1/23/20 |
1/27/20 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200123005725/en/
PUTNAM SHAREHOLDERS CONTACT: 1-800-225-1581
Source: Putnam Funds
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HCA Healthcare Reports Second Quarter 2026 Results
- ACCO Brands Corporation Declares Quarterly Dividend
- Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Putnam InvestmentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share